Parthenon Therapeutics Announces Publication in Journal for ImmunoTherapy of Cancer on the Role of PRTH-101 Inhibiting DDR1 in Immune Excluded Tumors

Parthenon Therapeutics has announced the publication of its research in the Journal for ImmunoTherapy of Cancer, which shows how PRTH-101 can inhibit collagen receptor discoid in domain receptor-1 (DDR1)-expressing cancer cells and reverse immune exclusion. The study was conducted with George Washington University and The University of Texas Health Center at Houston. Parthenon recently initiated..

  • format_list_bulleted BS
  • · 2023. 6. 26.
  • textsms

Parthenon Therapeutics Announces Publication in Journal for ImmunoTherapy of Cancer on the Role of PRTH-101 Inhibiting DDR1 in Immune Excluded Tumors

Parthenon Therapeutics has announced that a collaboration between the company, The University of Texas Health Center at Houston and George Washington University has demonstrated that PRTH-101 potently inhibits the adhesion of collagen receptor discoid in domain receptor-1 expressing cancer cells to collagen substrates and DDR1 autophosphorylation induced by collagen. The drug candidate binds to ..

  • format_list_bulleted BS
  • · 2023. 6. 23.
  • textsms

Parthenon Therapeutics Announces Publication in Journal for ImmunoTherapy of Cancer on the Role of Immune Exclusion in Cancer

Precision oncology company Parthenon Therapeutics has had an article published in the Journal for ImmunoTherapy of Cancer (JITC) that identified key characteristics and issues relevant to the role immune exclusion plays in resistance to checkpoint therapy. The work was performed in collaboration with multiple US and international academic institutions. Parthenon recently initiated a Phase 1 tria..

  • format_list_bulleted BS
  • · 2023. 6. 13.
  • textsms